Markets:

Overview

News

Currencies

International

Treasuries

Quest Diagnostics (NY:DGX)

226.80 +16.97 (+8.09%)

Streaming Delayed Price Updated: 3:10 PM EDT, Jul 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Quest Diagnostics

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

Expert Ratings for Quest Diagnostics ↗

December 07, 2023

Via Benzinga

Opioid Crisis and Corporate Accountability: Purdue's Settlement in the Spotlight ↗

December 04, 2023

The U.S. Supreme Court is reviewing a contentious bankruptcy settlement involving Purdue Pharma, the maker of OxyContin, and its owners, the Sackler family.

Via Benzinga

Topics Bankruptcy

Half Of S&P 500 Stocks Still Below 200-Day Average, Ignoring Covid-Like Rally: 10 Bargain Plays For Latecomer Bulls ↗

November 21, 2023

Explore the dichotomy in the latest S&P 500 rally: Strong overall performance masks the underperformance of nearly half its stocks.

Via Benzinga

Topics Stocks

Expert Ratings for Quest Diagnostics ↗

November 17, 2023

Via Benzinga

Firing on All Cylinders Indeed ↗

November 11, 2023

Investors are seeing some big reactions to earnings results in tech and have a few reasons to think some beaten-up names might be finding their footing.

Via The Motley Fool

Making Connections To Care: Quest Supports Inspiring Health Equity Event Hosted by Sisters on the Vineyard

August 28, 2023

Via ACCESSWIRE

Quest Diagnostics: Dividend Insights ↗

July 05, 2023

Via Benzinga

Quest Diagnostics Q3: 7.7% Topline Decline, Earnings Beat, Updated Guidance & More ↗

October 24, 2023

Quest Diagnostics Incorporated (NYSE: DGX) posted Q3 FY23 adjusted EPS of $2.22, down 5.9% Y/Y, beating the

Via Benzinga

Topics Earnings

Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030

October 17, 2023

EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NASDAQ:GH),(NASDAQ:NTRA),(NYSE:DGX),(NASDAQ:NEO) EQNX::TICKER_END

Via FinancialNewsMedia

Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready ↗

October 11, 2023

Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic tool. While several blood tests for Alzheimer's diagnosis are...

Via Benzinga

Analyst Ratings for Quest Diagnostics ↗

June 29, 2023

Via Benzinga

The Latest Analyst Ratings for Quest Diagnostics ↗

May 02, 2023

Via Benzinga

Will Chart Analysts Notice Bad Omen on Quest Diagnostics's Chart ↗

May 02, 2023

Via Benzinga

Quest Diagnostics Q1 Earnings Surpass Expectations; COVID-19 Testing Revenues Slump 80% ↗

April 27, 2023

Via Benzinga

Biden Administration Restarts Distribution Of Free At Home COVID-19 Tests, After Suspending For Year ↗

September 21, 2023

In response to the escalating spread of the virus nationwide, the Biden administration declared that it would recommence offering free at-home COVID tests to American households starting next Monday.

Via Benzinga

3 Pharma Stocks to Buy as Summer COVID Cases Spike ↗

August 23, 2023

Covid cases are on the rise, which might be the booster shot these top pharma stocks for Covid need to regain their trajectory.

Via InvestorPlace

Why Bionano Genomics Stock Tanked Today ↗

August 14, 2023

A CFO departure shines a light on some of the company's recent struggles.

Via The Motley Fool

More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection ↗

August 09, 2023

Alzheimer's is a huge problem, and earlier detection could make a big difference.

Via The Motley Fool

Looking for a Bargain? 3 Stocks to Buy That Are Down 10% in 2023 ↗

August 02, 2023

Investors looking for bargain stock opportunities in a rapidly-rising market should consider these companies that haven't yet bounced back.

Via InvestorPlace

Quest Diagnostics Stock Falls on Lower Q2 Revenue and Profits from Lower Productivity Effects, Tightened Outlook ↗

July 26, 2023

Quest Diagnostics Inc (NYSE: DGX) posted Q2 FY23 adjusted EPS of $2.30, down 2.5% Y/Y, beating the consensus of $2.27.

Via Benzinga

Sustaining Growth Momentum: Quest Diagnostics Continues to Excel and Reports Rising Profits ↗

July 25, 2023

At the end of July 25, 2023, Quest Diagnostics (NYSE:DGX) will reward its shareholders with a dividend payout of $0.71 per share, demonstrating an annualized dividend yield of 2.15%. Remember, only...

Via Benzinga

Quest Diagnostics, Keysight Technologies And A Stock Up 42% Year To Date On CNBC's 'Final Trades' ↗

July 19, 2023

On CNBC’s "Halftime Report Final Trades," Jason Snipe of Odyssey Capital Advisors said he likes Quest Diagnostics Incorporated (NYSE: DGX) here.

Via Benzinga

Biden Administration Releases Revised Guidance For Medicare Drug Price Negotiation Amid Industry Lawsuits ↗

June 30, 2023

The Centers for Medicare and Medicaid Services released revised guidance on using its authority with pharmaceutical manufacturers

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2023 ↗

June 29, 2023

Via Benzinga

FDA Readies Proposal for Increased Oversight on Lab-developed Tests ↗

June 08, 2023

The FDA is preparing to increase regulation of a widely used class of tests conducted by laboratories to detect cancer, measure cholesterol, and identify other health issues. The FDA is developing a...

Via Benzinga

Want Growing Passive Income? Consider Buying This Stock ↗

May 24, 2023

This maker of diagnostics tests has delivered 13 years of dividend growth to shareholders.

Via The Motley Fool

Post-Accident Workforce Drug Positivity For Marijuana Reached 25-Year High In 2022, Quest Diagnostics Drug Testing Index Analysis Finds ↗

May 18, 2023

The percentage of employees in the general U.S. workforce testing positive for marijuana following an on-the-job accident increased to its highest level in 25 years in 2022, according to a new analysis...

Via Benzinga

Exact Sciences Serves Investors Exactly What They Wished For

May 15, 2023

Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The

Via MarketBeat

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In May ↗

May 11, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2023 ↗

May 02, 2023

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.